

LIST OF TABLES

Table		Page
LITERATURE REVIEW		
1.	Pharmacokinetics of artemisinin and its derivatives in healthy subjects; data are presented as median (range) or mean \pm SD	18-23
2.	Pharmacokinetics of artemisinin and its derivatives in <i>P. falciparum</i> malaria patients; data are presented as median (range) or mean \pm SD	24-30
3.	Clinical trial of oral dihydroartemisinin in patients with severe or uncomplicated falciparum malaria; data are presented as mean \pm SD or percentage (radically cured cases/complete follow-up cases)	31-32
4.	Determinants of antimalarial drug resistance	38
CLINICAL EFFICACY OF MONOTHERAPY OF HIGH DOSE DIHYDROARTEMISININ OR COMBINATION THERAPY OF HIGH DOSE DIHYDROARTEMISININ AND MEFLUQUINE IN VIETNAMESE PATIENTS WITH UNCOMPLICATED FALCIPARUM MALARIA		
5.	Baseline clinical characteristics of patients; data are presented as number or mean \pm SD	53
6.	Baseline blood laboratory characteristics of patients; data are presented as number, mean \pm SD or median (range)	54
7.	Clinical and parasitological responses of patients; data are presented as number or mean \pm SD	55

LIST OF TABLES (cont.)

Table		Page
PHARMACOKINETICS OF MEFLOROQUINE WITH DIHYDROARTEMISININ AS 2-DAY REGIMENS IN PATIENTS WITH UNCOMPLICATED FALCIPARUM MALARIA		
8.	Demographic, baseline clinical and laboratory data on admission and treatment response in patients with acute uncomplicated falciparum malaria in regimen-A (an initial oral dose of 300 mg DHA followed by 750 mg MQ at 6 h and 300 mg DHA at 24 h) and regimen-B (an initial oral dose of 300 mg DHA followed by 750 mg MQ and 300 mg DHA at 24 h). Data are presented as median (range) or number (n) values	63
9.	Pharmacokinetic parameters of MQ when given as 750 mg at 0 (regimen-A) and 24 h (regimen-B) after an oral dose of DHA in Vietnamese male patients with uncomplicated falciparum malaria. Data are presented as median (range) values	65
DEVELOPMENT AND VALIDATION OF A LIQUID CHROMATOGRAPHY – MASS SPECTROMETRY METHOD FOR THE SIMULTANEOUS QUANTIFICATION OF ARTESUNATE AND DIHYDROARTEMISININ IN HUMAN PLASMA		
10.	LOD and LOQ of ARS; data are presented as mean \pm SD (n = 5)	82
11.	LOD and LOQ of DHA; data are presented as mean \pm SD (n = 5)	82
12.	Assay linearity	83
13.	The intra-day and inter-day variation of ARS concentrations (ng/ml); data are presented as mean \pm SD	85

LIST OF TABLES (cont.)

Table	Page
14. The intra-day and inter-day variation of DHA concentrations (ng/ml); data are presented as mean \pm SD	85
15. Extraction recovery; data are presented as mean \pm SD (n = 5)	86
16. ARS stability at 4°C; data are presented as mean \pm SD (n = 5)	86
17. ARS stability at room temperature; data are presented as mean \pm SD (n = 5)	87
18. ARS concentrations (ng/ml) in healthy volunteer receiving a single daily oral administration of 200 mg ARS for five consecutive days	87
19. DHA concentrations (ng/ml) in healthy volunteer receiving a single daily oral administration of 200 mg ARS for five consecutive days	87
20. Pharmacokinetics of ARS and DHA in healthy volunteer	89

PHARMACOKINETICS OF A FIVE-DAY ORAL DIHYDROARTEMISININ MONOTHERAPY REGIMEN IN PATIENTS WITH UNCOMPLICATED FALCIPARUM MALARIA

21. Baseline characteristics (n = 10); data are presented as median (range) or number (n)	100
22. Treatment responses (n = 10); data are presented as median (range) or number (n)	101
23. Plasma dihydroartemisinin concentrations (ng/ml) over five days	104

LIST OF TABLES (cont.)

Table	Page
24. Comparison of DHA plasma concentrations and pharmacokinetic parameters between day 0 and day 4; data are presented as median (range)	105
ABSENCE OF TIME DEPENDENCY IN ARTESUNATE PHARMACOKINETICS IN HEALTHY SUBJECTS FOLLOWING A FIVE- DAY ORAL ADMINISTRATION	
25. Baseline characteristics of 10 Vietnamese healthy male volunteers; data are presented as median (range)	115
26. DHA concentrations (ng/ml) following the administration of 200 mg oral doses of ARS once daily for 5 consecutive days	117
27. Pharmacokinetics of DHA following the administration of 200 mg oral doses of ARS once daily for 5 consecutive days; data are presented as median (range)	118
28. ARS concentrations (ng/ml) following the administration of 200 mg oral doses of ARS once daily for 5 consecutive days	119
29. ARS pharmacokinetics following the administration of 200 mg oral doses of ARS once daily over 5 consecutive days; data are presented as median (range)	120